Private Market View

MINGZE PHARMA

Beijing, China · Founded 2014 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Changxing Financial Holding, Huizhi Capital.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 2 names
  • ·Watchlist + deal alerts for MINGZE PHARMA
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for MINGZE PHARMA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About MINGZE PHARMA

Developer of pharmaceutical formulations designed to advance transdermal and topical drug delivery technologies. The company offers diversified research and development platforms covering transdermal patches, semi-solid formulations, and oral dosage forms, enabling pharmaceutical enterprises to accelerate drug development, achieve regulatory compliance, and enhance therapeutic efficacy.

Sector
Healthcare
HQ
Beijing, China
Founded
2014
Employees
18
Ownership
Privately Held (backing)
PA Mark — not yet priced

MINGZE PHARMA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in MINGZE PHARMA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on MINGZE PHARMA in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.